Gamma Knife radiosurgery is also called stereotactic radiosurgery, which is extremely accurate method of therapeutic radiology. It uses concentrated beams of gamma rays for treating small and medium size lesions in the brain without a surgical incision.
Technological Advancements to Provide Accurate Results
Based on the indications, segments are benign tumors, malignant tumors, vascular disorders, functional disorders, and ocular diseases. Malignant tumors estimated for maximum revenue share in 2016. Gamma knife therapy from Eleka AB is used as adjunct therapy for primary malignant brain tumors. It is a non-invasive stereotactic radiosurgery instrument that generally includes no incision. It uses up to 201 accurately focused beams of radiation for controlling malignant as well as nonmalignant tumors. It can be also used to treat vascular and functional disorders in the brain, without hurting nearby healthy tissue.
In addition, technological progressions have improved accuracy in surgery. For instance, recently Elekta AB announced a partnership with Palabra. The company will receive advantage of automation abilities and one-of-a-kind speech integration that can be combined into their MOSAIQ Oncology Information System. Palabra uses speech recognition techniques and automation technology for accelerating real-world clinical operations required for correct and complete records of the patients. These integrated systems are already installed in locations in Australia and North America.
In addition, technological progressions have improved accuracy in surgery. For instance, recently Elekta AB announced a partnership with Palabra. The company will receive advantage of automation abilities and one-of-a-kind speech integration that can be combined into their MOSAIQ Oncology Information System. Palabra uses speech recognition techniques and automation technology for accelerating real-world clinical operations required for correct and complete records of the patients. These integrated systems are already installed in locations in Australia and North America.
Ocular diseases segment is likely to grow at a lucrative rate of 12.1% during the estimated period. Gamma knife therapy is utilized for several ocular indications like advanced glaucoma, uveal melanoma, age-related macular degeneration, eye metastases, pseudotumor cerebri, and vegetative pain.
Market Overview
According to Grand View Research, Inc., the worldwide gamma knife market is likely to attain USD 239.2 million by 2025. Factors such as increasing prevalence of neurological diseases and cancers, increasing demand for minimally invasive surgeries (MIS), and technological developments in the device can drive market.
In 2016, Asia Pacific estimated for the major market share in terms of revenue owing to high incidence of brain tumors in the region and growing awareness of noninvasive procedures among the healthcare specialists.
The Elekta AB is the only company operating in the market as Gamma Knife is a patient protected trademark of company.
In-Depth Research Report On Gamma Knife Market:
https://www.grandviewresearch.com/industry-analysis/gamma-knife-market
No comments:
Post a Comment